Page last updated: 2024-09-04

cyc 202 and Hyperglycemia, Postprandial

cyc 202 has been researched along with Hyperglycemia, Postprandial in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benson, C; Cassidy, J; Cruickshank, C; De Bono, J; Gianella-Borradori, A; Judson, I; Kaye, S; McGrath, H; O'Donnell, A; Raynaud, F; Twelves, C; Walton, M; White, J; Workman, P	1

Trials

1 trial(s) available for cyc 202 and Hyperglycemia, Postprandial

Article	Year
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Purines; Roscovitine; Treatment Outcome	2007

Article

Year

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.

British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Purines; Roscovitine; Treatment Outcome

2007